Recorded fact · drug.label_indication
drug.label_indication for capmatinib-hydrochloride|non-small-cell-lung-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact b7156987 resolves to.
The record
| Fact id | b715698710217f2bb9eabc0e |
|---|---|
| Entity | drug: capmatinib-hydrochloride|non-small-cell-lung-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20251215 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 4dde56d65e9150565e50d751c8ec87b0cad91bdd74e2f404dcd7add257e0b2ee.
The value
{
"ingredient": "Capmatinib Hydrochloride",
"conditionId": "non-small-cell-lung-cancer",
"conditionName": "Non-Small Cell Lung Cancer",
"matchedAlias": "non-small cell lung cancer",
"context": "indication",
"brand": "TABRECTA",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "455892c3-d144-4ba8-9ab4-79cabff9876d",
"labelEffectiveTime": "20251215",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 06ce81a40613a869aac336b255f5fb8e01b52c7b70e0174ce1c319d9e84097f1.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.